“Immunogenicity of Guselkumab (GUS) Among Psoriasis Patients in VOYAGE (VOY) 1&2 Studies”. 2022. SKIN The Journal of Cutaneous Medicine 6 (2): s11. https://doi.org/10.25251/skin.6.supp.11.